MedPacto Wins FDA Approval to Modify Phase 1/2 Vactosertib Trial in Osteosarcoma

Bitget2026/10/19 02:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MedPacto received FDA clearance on October 19, 2026, to modify its Phase 1/2 trial of vactosertib monotherapy for osteosarcoma.
The trial targets adolescents and adults with relapsed, refractory or progressive disease.
Researchers will compare 200 mg and 300 mg twice-daily doses for efficacy and safety to identify the optimal dose.
The study is scheduled to finish on February 29, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedPacto Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261019900196), on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MedPacto Wins FDA Approval to Modify Phase 1/2 Vactosertib Trial in Osteosarcoma

You may also like

Crypto prices